What is Aether?
Aether Biomachines is at the forefront of AI-driven protein discovery, developing a proprietary Protein Function Model capable of designing new proteins with specific, novel functions. Led by CEO and Founder Pavle Jeremi, the company leverages advanced high-throughput screening and innovative assay technology to build its unique dataset. This approach positions Aether to address critical needs across various industries by creating proteins for high-impact, real-world applications, moving beyond traditional biological discovery methods.
How much funding has Aether raised?
Aether has raised a total of $64.2M across 3 funding rounds:
Debt
$150K
Series A
$49M
Other Financing Round
$15M
Debt (2020): $150K with participation from PPP
Series A (2023): $49M led by Trevor Zimmerman and Jay Zaveri
Other Financing Round (2025): $15M supported by Tribe Management, Henkel Ventures, 4DX Ventures, and Shrug Capital
Key Investors in Aether
Tribe Management
Tribe Management, operating as Tribe Capital, is a venture capital firm based in Menlo Park, California, established in June 2018. The firm specializes in leveraging AI and data science to strategically deploy capital into N-of-1 companies, with a portfolio spanning fintech, healthcare, and enterprise software.
Henkel Ventures
Henkel Ventures is the Corporate Venture Capital arm of Henkel, focusing on providing funding and strategic partnerships to early-stage startups, particularly in sustainability and digitalization. They aim to drive innovation by leveraging Henkel's extensive network and expertise.
4DX Ventures
4DX Ventures is an early-stage venture capital firm established in 2017 and based in Ghana, Africa, with a specific focus on investments within the African continent.
What's next for Aether?
The recent major strategic investment in Aether Biomachines, following substantial prior capital raises, indicates a strong market validation and a clear trajectory towards scaling its innovative protein discovery platform. This influx of funding is expected to accelerate the company's research and development efforts, potentially expanding its proprietary dataset and enhancing the capabilities of its AI-driven Protein Function Model. Aether is poised to further solidify its position in the biotechnology and AI sectors, driving innovation in protein engineering and its application across diverse industries.
See full Aether company page
